Department of Biochemistry and Immunology, Birmingham Heart of England NHS Foundation Trust, Bordesley Green East, Birmingham B95SS, UK.
Ann Clin Biochem. 2010 Sep;47(Pt 5):467-75. doi: 10.1258/acb.2010.010060. Epub 2010 Aug 2.
Measurement of metadrenalines has been recommended in the investigation of phaeochromocytoma. Urinary assays remain the most common; however, drug interference is still one of the main challenges for analytical systems. We have developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantification of total urinary normetadrenaline and total urinary metadrenaline, which does not require extraction procedures prior to analysis.
Total urinary normetadrenaline and total urinary metadrenaline were individually quantified by electrospray ionization in the multiple-reaction monitoring mode. Deuterated internal standards were used and an acid hydrolysis step was used to convert conjugated metabolites into free metadrenalines. Chromatographic separation was achieved using a Phenomenex Luna 3 micro PFP column followed by analysis on an API 3200 LC-MS/MS.
Linearity was exhibited across the calibration range for both normetadrenaline (r = 1, P < 0.0001) and metadrenaline (r = 1, P < 0.0001) with the limit of quantification of 0.05 and 0.02 micromol/L, respectively. Intra-assay imprecision for both normetadrenaline and metadrenaline was less than 5.5% with % coefficient of variations of less than 4%. Inter-assay imprecision was less than 13%. Neither noradrenaline or adrenaline interfere with the assay as determined by the spiking of samples with high concentrations of noradrenaline or adrenaline (P > 0.05). Acceptable analytical performance was seen with comparison to a high-performance liquid chromatography method and on External Quality Assessment returns.
An analytically simple and sensitive method has been developed and evaluated for the analysis of total urinary normetadrenaline and total urinary metadrenaline which is now in routine use.
在嗜铬细胞瘤的研究中,已推荐测定去甲肾上腺素。尿液检测仍然是最常见的方法;然而,药物干扰仍然是分析系统的主要挑战之一。我们已经开发了一种液相色谱-串联质谱(LC-MS/MS)方法,用于定量分析总尿去甲肾上腺素和总尿间甲肾上腺素,该方法在分析前不需要提取程序。
总尿去甲肾上腺素和总尿间甲肾上腺素分别通过电喷雾电离在多重反应监测模式下进行定量。使用氘代内标,并采用酸水解步骤将结合代谢物转化为游离间甲肾上腺素。采用 Phenomenex Luna 3 micro PFP 柱进行色谱分离,然后在 API 3200 LC-MS/MS 上进行分析。
线性范围均为 0.05-0.10 μmol/L(r = 1,P < 0.0001)和 0.02-0.06 μmol/L(r = 1,P < 0.0001),用于测定去甲肾上腺素和间甲肾上腺素的定量下限分别为 0.05 和 0.02 μmol/L。两种物质的日内精密度均小于 5.5%,变异系数均小于 4%。日间精密度均小于 13%。通过向高浓度去甲肾上腺素或肾上腺素样品中添加内标进行测定,发现去甲肾上腺素或肾上腺素不会干扰测定(P > 0.05)。与高效液相色谱法和外部质量评估结果相比,该方法具有可接受的分析性能。
已经开发并评估了一种分析简单且灵敏的方法,用于分析总尿去甲肾上腺素和总尿间甲肾上腺素,现已常规使用。